Lymphoma Clinical Trials in California

Showing 361-370 of 370 trials

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00090090

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Mantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Spectrum Pharmaceuticals, Inc114 participantsStarted Apr 2004

Berkeley, California, United States • Burbank, California, United States • Los Angeles, California, United States +4 more locations

TERMINATEDPhase 2136 miles

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

NCT00120198

Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.

Non-Hodgkin's Lymphoma

Geriatric Oncology Consortium50 participantsStarted Mar 2005

Oxnard, California, United States • Washington D.C., District of Columbia, United States • Inverness, Florida, United States +2 more locations

COMPLETEDPhase 2160 miles

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

NCT00045864

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.

Lymphoma, Non-Hodgkin

Chiron Corporation

Tucson, Arizona, United States • Newport Beach, California, United States • Sacramento, California, United States +30 more locations

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Lymphoma Trials in Other Cities

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Other Conditions in California